Helius Medical Technologies, Inc. to Present at Four Upcoming Investor Conferences in January
January 04 2021 - 07:05AM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced that management will participate in the
following upcoming investor conferences in January:
The Demy-Colton Digital Medicine and Medtech Showcase
2021, which is being held virtually from January
11th-15th.
-
The Company’s presentation will be available on-demand beginning on
Wednesday, January 6th at 8:30 a.m. Eastern Time.
The H.C. Wainwright BioConnect Conference, which is
being held virtually from January
11th-14th.
-
The Company’s presentation will be available on-demand beginning on
Monday, January 11th at 6:00 a.m. Eastern Time.
The Sidoti Winter 2021 Investor Conference, which is
being held virtually from January
13th-14th.
-
Management will present on Wednesday, January 13th at 1:45 p.m.
Eastern Time.
The ICR Conference 2021, which is being held virtually
from January
11th-14th.
-
Management will present on Thursday, January 14th at 10:45 a.m.
Eastern Time.
Webcasts of the presentations will be provided
under the ‘Events’ section of the Helius Medical Technologies
investor relations website at
https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.
Archives of the webcasts will be available for replay following the
conference.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech
company focused on neurological wellness. The Company’s purpose is
to develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNSTM). For more information, visit
www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™)
is authorized for sale in Canada as a class II, non-implantable,
medical device intended as a short term treatment (14 weeks) of
gait deficit due to mild and moderate symptoms from multiple
sclerosis (MS), and chronic balance deficit due to mild-to-moderate
traumatic brain injury (mmTBI) and is to be used in conjunction
with physical therapy. The PoNS™ is an investigational medical
device in the United States, the European Union (“EU”), and
Australia (“AUS”). The device is currently under review for
clearance by the FDA. It is also under premarket review by the AUS
Therapeutic Goods Administration. PoNS™ is currently not
commercially available in the United States, the European Union or
Australia.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies,
Inc.Mike Piccinino, CFAinvestorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2023 to Mar 2024